All News about Bioxcel Therapeutics Inc
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/05/25/dollar_tree_-_logo.jpg?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/733985/usual-day-in-crowded-nursing-home.jpg)
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](/next-assets/images/schema-image-default.png)
The Latest Analyst Ratings for BioXcel Therapeutics
May 09, 2023
Via Benzinga
![](https://g.foolcdn.com/editorial/images/731555/chalk.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/05/25/btai.png?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2022/05/Stock-drugsdish-01-adobe.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/05/16/aapharma_7.png?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/732173/chalk.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/05/08/stock_art.jpg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2019/09/Stock-drug-63-adobe.jpg)
![](/next-assets/images/schema-image-default.png)
BioXcel Therapeutics's Earnings Outlook
May 05, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
6 Analysts Have This to Say About BioXcel Therapeutics
March 10, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Earnings Preview: BioXcel Therapeutics
March 08, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Expert Ratings for BioXcel Therapeutics
February 08, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2023/05/TECH1_neuro_050523_adobe.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/03/21/image27_2.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://g.foolcdn.com/editorial/images/713185/patient-checking-in-for-a-doctors-appointment.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_8426.png?width=1200&height=800&fit=crop)
Analyst Ratings for BioXcel Therapeutics
December 01, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/02/14/btai_mark_composite_dark__11d783dab1a5bdea8a0dd7c2b444adda.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/02/08/btai_logo_light__7dc11bc8700604be125270d17e7d1ef5.png?width=1200&height=800&fit=crop)
Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023
February 08, 2023
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2023/01/Stock-AIbiotech-01-adobe.jpg)
![](https://www.investors.com/wp-content/uploads/2019/01/stock-gene-03-adobe.jpg)
![](https://g.foolcdn.com/editorial/images/709692/doctor-holding-elderly-patients-hand.jpg)
Is This Soaring Growth Stock a Buy?
November 20, 2022
Via The Motley Fool
![](https://g.foolcdn.com/editorial/images/711241/pharmacist-talking-to-patient.jpg)
![](https://g.foolcdn.com/editorial/images/711663/person-in-a-lab-looking-through-a-microscope.jpg)
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
December 01, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.